TUSTIN, Calif., May 30 /PRNewswire-FirstCall/ -- AMDL, Inc. , www.amdl.com ,a world leader in specialty pharmaceuticals with operations in Shenzhen, Jiangxi and Jilin, China, announced today the launch of new products for its GOODNAK anti-aging line.
The company is releasing the new GOODNAK formulations in partnership with JJB, the subsidiary of AMDL's Chinese subsidiary Jade Pharmaceutical Inc. (JPI). Scheduled to be released next month, the GOODNAK product includes Human Placental Histosolution, and effective and key component in anti-aging products which has been shown to give skin a youthful look by increasing cell renewal and smoothening fine lines.
JJB has applied to Chinese regulatory authorities for product approval and anticipates sanction this month. Based on the general market information, the proposed pricing for the new GOODNAK products is anticipated to be approximately (U.S.)$40.00 per unit with a 60% gross profit margin.
Frank Zhang, managing Director of JPI, stated that, "the new GOODNAK consumer products are expected to be highly popular and anticipated sales growth is expected to significantly increase in 2008 and beyond. This product may also be extremely an exceptionally good candidate for export to the North American and European beauty care markets."
AMDL, Inc. is a global specialty pharmaceutical company. The Company is headquartered in Tustin, California with operations in Shenzhen, Jiangxi, and Jilin, China. Along with its subsidiary Jade Pharmaceutical Inc. (JPI), AMDL is devoted to the research, development, manufacture, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products currently in China. The company employs approximately 320 people in the U.S. and China. More information about AMDL and its products can be obtained at http://www.amdl.com.
About Jade Pharmaceutical:
JPI has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiaries, Jade currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.
IR Contact: Mr. Paul Knopick
CONTACT: Mr. Paul Knopick, +1-949-707-5365, +1-714-505-4460 voicemail
Web site: http://www.amdl.com/